Avalo Therapeutics, Inc. - Form 8-K Summary
Business Context and Reporting Period
This Form 8-K reports on the results of the 2025 Annual Meeting of Stockholders held on June 17, 2025. Avalo Therapeutics, Inc. is a Delaware corporation with its common stock (AVTX) listed on the Nasdaq Capital Market.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance and voting outcomes.
Material Changes and Voting Results
As of the record date (April 22, 2025), there were 10,827,620 shares outstanding. Approximately 90% of shares (9,787,648) were present or represented by proxy. The following proposals were voted upon:
- Proposal 1 (Election of Directors): All eight nominees were elected to the Board. Voting results varied by nominee, with significant broker non-votes (1,758,985) recorded for each. Notably, June Almenoff and Mitchell Chan received approximately 88% of the votes cast "For," while other nominees received over 99%.
- Proposal 2 (Say-on-Pay): The nonbinding advisory resolution regarding executive compensation was approved with 8,003,142 votes "For" and 23,285 votes "Against."
- Proposal 3 (Ratification of Auditors): The appointment of Ernst & Young LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2025, was overwhelmingly approved with 9,782,455 votes "For" and only 5,058 votes "Against."
Guidance, Outlook, and Risks
The filing text does not provide a clear value for future guidance, management commentary on financial outlook, specific risks, contingencies, or unusual items. The document is limited to the disclosure of voting results.
Key Facts for Investor Verification
- Verify the specific reasons for the lower "For" vote percentages for directors June Almenoff and Mitchell Chan compared to other board members.
- Confirm the total number of shares outstanding and the record date (April 22, 2025) for future proxy calculations.
- Note that Ernst & Young LLP has been ratified as the auditor for the fiscal year ending December 31, 2025.
- Review the full proxy statement for details on the "Say-on-Pay" compensation metrics, as this 8-K only provides the vote tally.